Company news

Gilead Sciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta® in Patients With Relapsed or Refractory Large B-cell lymphoma

February 9, 2021

Kite Appoints Frank Neumann as Worldwide Head of Clinical Development

February 7, 2021

Gilead Sciences Announces 4.4 Percent Increase in First Quarter 2021 Dividend

February 3, 2021

Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone’s Vaccine Platform Technology for HIV Cure

January 31, 2021

Gilead Sciences to Release Fourth Quarter and Full Year 2020 Financial Results on Thursday, February 4, 2021

January 20, 2021

Francesco M. Marincola Joins Kite as Worldwide Head of Cell Therapy Research

January 18, 2021

Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus

January 11, 2021

Gilead Sciences Announces Updated 2020 Guidance

January 10, 2021

Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors

January 5, 2021

Kite’s Tecartus™ (KTE-X19) Granted Conditional Marketing Authorization for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma in Europe

December 15, 2020

Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca® (Filgotinib)

December 14, 2020

Gilead Sciences to Acquire MYR GmbH

December 9, 2020

Gilead Announces Racial Equity Community Impact Fund to Support Black Communities Across United States

December 8, 2020

Jeffrey A. Bluestone Joins Gilead Sciences’ Board of Directors

December 7, 2020

Gilead Announces Investigational Long-Acting HIV-1 Capsid Inhibitor, Lenacapavir, Achieves Primary Endpoint in Phase 2/3 Study in Heavily Treatment-Experienced People Living With HIV

November 17, 2020

Gilead Sciences Announces Fourth Quarter 2020 Dividend

October 27, 2020

Gilead Sciences Completes Acquisition of Immunomedics, Inc.

October 22, 2020

U.S. Food and Drug Administration Approves Gilead’s Antiviral Veklury® (remdesivir) for Treatment of COVID-19

October 21, 2020

Gilead Announces New Data on Biktarvy® for the Treatment of HIV in Black Americans

October 20, 2020

Gilead Sciences to Release Third Quarter 2020 Financial Results on Wednesday, October 28, 2020

October 13, 2020

Gilead Sciences Signs Joint Procurement Agreement With the European Commission for Veklury® (remdesivir)

October 7, 2020

Gilead Presents Biktarvy® Findings From Switch Studies & Analysis of Real-World BICSTaR Study At HIV Glasgow 2020

October 4, 2020

Gilead Sciences Update on Supply and Distribution of Veklury® (remdesivir) in the United States

September 30, 2020

Jyseleca® (Filgotinib) Approved in Japan for Rheumatoid Arthritis

September 24, 2020

← Newer news releases

Calls

The 5 newest of 26 calls. Every call is listed under its year.

Decks

The 5 newest of 51 decks. Every deck is listed under its year.